Favorable impact in hepatitis C–related mortality following free access to direct‐acting antivirals in Spain
Julieta Politi, Juan‐Miguel Guerras, Marta Donat, María J. Belza, Elena Ronda, Gregorio Barrio, Enrique Regidor – 11 November 2021
Immunogenicity and Adverse Effects of the 2‐Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients
Yana Davidov, Keren Tsaraf, Oranit Cohen‐Ezra, Mariya Likhter, Gil Ben Yakov, Itzchak Levy, Einav G. Levin, Yaniv Lustig, Orna Mor, Galia Rahav, Ziv Ben Ari – 11 November 2021 – The BNT162b2 messenger RNA (mRNA) vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been shown to be safe and effective in immunocompetent patients. The safety and efficacy of this vaccine in liver transplantation (LT) recipients is still under evaluation. The objective of this study was to assess the safety and efficacy of the BNT162b2 vaccine among transplant recipients.
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma
Lu Tian, Luqing Zhao, Karen Man‐Fong Sze, Charles Shing Kam, Vanessa Sheung‐In Ming, Xia Wang, Vanilla Xin Zhang, Daniel Wai‐Hung Ho, Tan‐To Cheung, Lo‐Kong Chan, Irene Oi‐Lin Ng – 11 November 2021
Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1
Juan Yang, Jianming Ye, Tengfei Ma, Fangfang Tang, Li Huang, Zhen Liu, Song Tian, Xu Cheng, Li Zhang, Zhenli Guo, Fuping Tu, Miao He, Xueming Xu, Xiaojuan Lu, Yanyang Wu, Xiaoli Zeng, Jiahua Zou, Xiangcai Wang, Weijie Peng, Peng Zhang – 11 November 2021
A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome
Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee – 11 November 2021
LiverLearning®: 2021 Hepatitis Debrief
Digest a debrief of the newest data on the treatment of viral hepatitis presented at The Liver Meeting® 2021. This unique session synthesizes the results from this years abstracts, condensed and discussed by an expert in the field.
LiverLearning®: 2021 Cholestatic and Autoimmune Liver Diseases SIG: Overlap Syndromes: A Special Interest Group Update
What is the latest evidence to guide hepatologists in the management of patients with challenging overlap syndromes, such as PBC-AIH and PSC-AIH? At this stimulating program, faculty will address current controversies related to the pathogenesis, diagnosis, and management of overlap syndromes, including how to distinguish different phenotypes and select appropriate therapeutics for these patients.
LiverLearning®: 2021 HBV Global Symposium
The newest global strategies to manage patients with hepatitis B virus (HBV) will be discussed at this intriguing symposium. Topics include the current state of HBV research, surveillance for hepatocellular carcinoma in HBV, HBV management during pregnancy, and novel and emerging therapies for both HBV and hepatitis D.
LiverLearning®: 2021 Postgraduate Course - Part I, II and III: Managing the Epidemic of Fatty Liver from Obesity and Alcohol
Nonalcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease are two principal causes of advanced liver disease in the U.S., and both contribute heavily to rising incidence of hepatocellular carcinoma. Faculty will identify drivers of disease progression in both diseases, provide guidance on optimal management strategies, and discuss emerging therapeutic options most likely to be in the future treatment armamentarium.
LiverLearning®: 2021 AASLD/ALEH Joint Symposium: The State of Modern Hepatology in the Americas
What diagnostic, prevention and therapeutic challenges do global hepatologists face as they manage patients with complex liver conditions in 2021 and beyond? This session will contrast modern hepatology practice in the English- and Spanish/Portuguese-speaking Americas in the strategic management of HBV, including diagnosis challenges and prevention gaps, and NAFLD, including efforts to decrease disease burden.